LinkedIn

آمار

تعداد نشریات20
تعداد شماره‌ها995
تعداد مقالات9,123
تعداد مشاهده مقاله10,697,182
تعداد دریافت فایل اصل مقاله5,161,803
Pouresmaeil, Vahid, Mohammadpour, Amir Hooshang, Ariabod, Vahid, Pourtaji, Atena. (1401). A New Pre-Treatment Approach in Ulcerative Colitis in a mice model. سامانه مدیریت نشریات علمی, 10(4), -. doi: 10.30476/acrr.2023.97512.1164
Vahid Pouresmaeil; Amir Hooshang Mohammadpour; Vahid Ariabod; Atena Pourtaji. "A New Pre-Treatment Approach in Ulcerative Colitis in a mice model". سامانه مدیریت نشریات علمی, 10, 4, 1401, -. doi: 10.30476/acrr.2023.97512.1164
Pouresmaeil, Vahid, Mohammadpour, Amir Hooshang, Ariabod, Vahid, Pourtaji, Atena. (1401). 'A New Pre-Treatment Approach in Ulcerative Colitis in a mice model', سامانه مدیریت نشریات علمی, 10(4), pp. -. doi: 10.30476/acrr.2023.97512.1164
Pouresmaeil, Vahid, Mohammadpour, Amir Hooshang, Ariabod, Vahid, Pourtaji, Atena. A New Pre-Treatment Approach in Ulcerative Colitis in a mice model. سامانه مدیریت نشریات علمی, 1401; 10(4): -. doi: 10.30476/acrr.2023.97512.1164

A New Pre-Treatment Approach in Ulcerative Colitis in a mice model

Iranian Journal of Colorectal Research
مقاله 4، دوره 10، شماره 4، اسفند 2022  XML اصل مقاله (2.58 M)
نوع مقاله: Research/Original Article
شناسه دیجیتال (DOI): 10.30476/acrr.2023.97512.1164
نویسندگان
Vahid Pouresmaeil email orcid 1؛ Amir Hooshang Mohammadpourorcid 2؛ Vahid Ariabodorcid 3؛ Atena Pourtajiorcid 4
1Department of Biochemistry, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.
2Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
3Department of Pathology, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.
4Pharmaceutical Research Center, Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
چکیده
Background: Inflammatory Bowel Disease (IBD) is a complex multifactorial disease that includes two Crohn's disease and ulcerative colitis (UC). The UC characterized by inflammation, oxidative stress, and increased intestinal epithelial cell apoptosis. The present study aiming to investigate the protective potential of a combination of five safety products: Bromelain (BR), Silibinin (SB), Alpha-lipoic acid (ALA), Inulin (IN) and Sodium butyrate (BU) against UC.
Methods: Seventy-two male Balb/c mice were divided into 9 groups, and administered for 14 days by a minimum effective dose of BR, SB, ALA, IN, BU or all together (PAC). Mesalazine (MZ) is used to compare the therapeutic effects of the compounds. Colitis was induced by rectal injection of acetic acid (4%) in 12th day. Blood and colon tissue were collected and the expression of inflammatory cytokines, and oxidative stress indices were examined using ELISA methods. The SPSS v.24 was used for data analysis.
Results: All the therapeutic groups including BR, IN, BU, ALA, SB separately, partially improved histopathological changes due to colitis, but PAC treatment prior to colitis induction significantly (p<0.001), and more effectively alleviated the extent and intensity of the histological signs of cell damage including inflammation intensity, macroscopic and microscopic colon damage, and improved colitis. A significant decrease in inflammatory cytokines and oxidative stress indices also observed in the group treated with ALA, SB and PAC.
Conclusion: This new drug combination (PAC) is more beneficial for the prevention of UC better than MZ that is a usual treatment of UC.
کلیدواژه‌ها
Ulcerative Colitis؛ Oxidative Stress؛ Inflammatory Cytokines؛ Preventive Drug
مراجع
 1. Feuerstein JD, Cheifetz AS, editors.
Ulcerative colitis: epidemiology,
diagnosis, and management. Mayo
Clinic Proceedings; 2014: Elsevier.
2. Ling K-L, Ooi C-J, Luman W, Cheong
W-K, Choen FS, Ng H-S. Clinical
Characteristics of Ulcerative Colitis
in Singapore, a Multiracial City–State.
Journal of clinical gastroenterology.
2002;35(2):144-8.
3. Lok KH, Hung HG, Ng CH,
Kwong KC, Yip WM, Lau SF,
et al. Epidemiology and clinical
characteristics of ulcerative colitis in
Chinese population: experience from
a single center in Hong Kong. Journal
of gastroenterology and hepatology.
2008;23(3):406-10.
4. Jantchou P, Morois S, Clavel-Chapelon
F, Boutron-Ruault M-C, Carbonnel
F. Animal protein intake and risk
of inflammatory bowel disease:
The E3N prospective study. The
American journal of gastroenterology.
2010;105(10):2195.
5. Jowett S, Seal C, Pearce M, Phillips
E, Gregory W, Barton J, et al.
Influence of dietary factors on the
clinical course of ulcerative colitis:
a prospective cohort study. Gut.
2004;53(10):1479-84.
6. Travis S, Stange E, Lémann M,
Øresland T, Bemelman W, Chowers
Y, et al. European evidence-based
consensus on the management
of ulcerative colitis: current
management. Journal of Crohn’s and
Colitis. 2008;2(1):24-62.
7. Wolfe MM, Lichtenstein DR, Singh
G. Gastrointestinal toxicity of
nonsteroidal antiinflammatory drugs.
New England Journal of Medicine.
1999;340(24):1888-99.
8. Mowat C, Cole A, Windsor A,
Ahmad T, Arnott I, Driscoll R, et al.
Guidelines for the management of
inflammatory bowel disease in adults.
Gut. 2011;60(5):571-607.  9. Nitzan O, Elias M, Peretz A, Saliba
W. Role of antibiotics for treatment
of inflammatory bowel disease.
World journal of gastroenterology.
2016;22(3):1078.
10. Connell W, Kamm M, Ritchie J,
Lennard-Jones J. Bone marrow
toxicity caused by azathioprine in
inflammatory bowel disease: 27 years
of experience. Gut. 1993;34(8):1081-5.
11. Hayes CE, Cerezo CS. Monoclonal
Antibody Use in Inflammatory Bowel
disease. Medicine and Health Rhode
Island. 2011;94(11):337.
12. Abdelouhab K, Rafa H, Toumi
R, Bouaziz S, Medjeber O, TouilBoukoffa C. Mucosal intestinal
alteration in experimental colitis
correlates with nitric oxide production
by peritoneal macrophages: effect
of probiotics and prebiotics.
Immunophar macology and
immunotoxicology. 2012;34(4):590-7.
13. Hale LP, Greer PK, Trinh CT, Gottfried
MR. Treatment with oral bromelain
decreases colonic inflammation in
the IL-10-deficient murine model of
inflammatory bowel disease. Clinical
Immunology. 2005;116(2):135-42.
14. Kane S, Goldberg MJ. Use of
bromelain for mild ulcerative
colitis. Annals of internal medicine.
2000;132(8):680.
15. Chobotova K, Vernallis AB, Majid
FAA. Bromelain’s activity and
potential as an anti-cancer agent:
current evidence and perspectives.
Cancer letters. 2010;290(2):148-56.
16. Leenen CH, Dieleman LA. Inulin and
oligofructose in chronic inflammatory
bowel disease. The Journal of
Nutrition. 2007;137(11):2572S-5S.
17. Guarner F. Inulin and oligofructose:
impact on intestinal diseases and
disorders. British Journal of Nutrition.
2005;93(S1):S61-S5.
18. Vernia P. Butyrate in the treatment of
ulcerative colitis. Digestive and Liver
Disease Supplements. 2007;1(1):27-30.
19. Schnekenburger M, Diederich M.
Nutritional epigenetic regulators
in the field of cancer: new avenues
for chemopreventive approaches.
Epigenetic cancer therapy: Elsevier;
2015. p. 393-425.
20. Kolgazi M, Jahovic N, Yüksel M,
Ercan F, Alican I. α‐Lipoic acid
modulates gut inflammation induced
by trinitrobenzene sulfonic acid in
rats. Journal of gastroenterology and
hepatology. 2007;22(11):1859-65.
21. Zheng R, Ma J, Wang D, Dong W,
Wang S, Liu T, et al. Chemopreventive
Effects of Silibinin on ColitisAssociated Tumorigenesis by
Inhibiting IL-6/STAT3 Signaling
Pathway. Mediators of inflammation
2018;2018.
22. Wan P, Chen H, Guo Y, Bai
A-P. Advances in treatment of
ulcerative colitis with herbs:
from bench to bedside. World
Journal of Gastroenterology: WJG.
2014;20(39):14099.
23. Vieira EL, Leonel AJ, Sad AP, Beltrão
NR, Costa TF, Ferreira TM, et al. Oral
administration of sodium butyrate
attenuates inflammation and mucosal
lesion in experimental acute ulcerative
colitis. The Journal of nutritional
biochemistry. 2012;23(5):430-6.
24. Trivedi P, Jena G. Role of α-lipoic acid
in dextran sulfate sodium-induced
ulcerative colitis in mice: studies
on inflammation, oxidative stress,
DNA damage and fibrosis. Food and
chemical toxicology. 2013;59:339-55.
25. Kauntz H, Bousserouel S, Gosse
F, Marescaux J, Raul F. Silibinin,
a natural flavonoid, modulates the
early expression of chemoprevention
biomarkers in a preclinical
model of colon carcinogenesis.
International journal of oncology.
2012;41(3):849-54.
26. Atarbashe RK, Abu-Raghif A.
Comparative treatment of induced
ulcerative colitis in male rat model by
using cinnarizine and sulfasalazine.
Iraqi Journal of Veterinary Sciences.
2020;34(2):465-72.
27. Mousavizadeh K, Rahimian R,
Fakhfouri G, Aslani F, Ghafourifar
P. Anti‐inflammatory effects of 5‐HT3
receptor antagonist, tropisetron on
experimental colitis in rats. European
journal of clinical investigation.
2009;39(5):375-83.
28. Rachmilewitz D, Karmeli F,
Takabayashi K, Hayashi T,
Leider-Trejo L, Lee J, et al.
Immunostimulatory DNA ameliorates
experimental and spontaneous
murine colitis. Gastroenterology.
2002;122(5):1428-41.
29. Pavan R, Jain S, Kumar A. Properties
and therapeutic application of
bromelain: a review. Biotechnology
research international. 2012;2012.
30. Johannsen F. Toxicological profile
of carboxymethyl inulin. Food and
chemical toxicology. 2003;41(1):49-59.
31. Egorin MJ, Yuan Z-M, Sentz DL,
Plaisance K, Eiseman JL. Plasma
pharmacokinetics of butyrate after
intravenous administration of sodium
butyrate or oral administration of
tributyrin or sodium butyrate to mice
and rats. Cancer chemotherapy and
pharmacology. 1999;43(6):445-53.
32. Cremer D, Rabeler R, Roberts A,
Lynch B. Safety evaluation of α-lipoic
acid (ALA). Regulatory Toxicology
and Pharmacology. 2006;46(1):29-41
33. Abenavoli L, Capasso R, Milic
N, Capasso F. Milk thistle in
liver diseases: past, present,
future. Phytotherapy Research.
2010;24(10):1423-32.
34. K hoshak hlagh P B-SM,
Mohammadirad A, Ashtaral-Nakhai
L, Minaie B, Abdollahi M. . Beneficial
effect of phosphodiesterase-5 inhibitor
in experimental inflammatory bowel
disease; molecular evidence for
involvement of oxidative stress. .
Toxicology mechanisms and methods.
2007;17(5):281-8.
35. Araki Y, Sugihara H, Hattori T. The
free radical scavengers edaravone
and tempol suppress experimental
dextran sulfate sodium-induced colitis
in mice. International journal of
molecular medicine. 2006;17(2):331-4.
36. Rees V. Chronic experimental colitis
induced by dextran sulphate sodium
(DSS) is characterized by Th1 and Th2
cytokines. Clinical & Experimental
Immunology. 1998;114(3):385-91.
37. Nishiyama Y, Kataoka T, Yamato K,
Taguchi T, Yamaoka K. Suppression
of dextran sulfate sodium-induced
colitis in mice by radon inhalation.
Mediators of inf lammation.
2012;2012.
38. Rathnavelu V, Alitheen NB, Sohila
S, Kanagesan S, Ramesh R. Potential
role of bromelain in clinical and
therapeutic applications. Biomedical
reports. 2016;5(3):283-8.
39. Nicola WG, Girgiss MW, El-Arab
AME, Habib DF, Elnemr ME,
Ahmed NM. Role of Inulin in the
Protection and Management of
Metabolic Inflammation in Humans
by. Biomedical and Pharmacology
Journal. 2018;11(2):1083-90.
40. Bach Knudsen K, Lærke H,
Hedemann M, Nielsen T, Ingerslev
A, Gundelund Nielsen D, et al.
Impact of diet-modulated butyrate
production on intestinal barrier
function and inflammation. Nutrients.
2018;10(10):1499.
41. Kiemer AK, Müller C, Vollmar AM.
Inhibition of LPS‐induced nitric oxide
and TNF‐α production by α‐lipoic acid
in rat Kupffer cells and in RAW 264.7
murine macrophages. Immunology
and cell biology. 2002;80(6):550-7.
42. Tong W, Zhang C, Hong T, Liu D,
Wang C, Li J, et al. Silibinin alleviates
inflammation and induces apoptosis
in human rheumatoid arthritis
fibroblast-like synoviocytes and has
a therapeutic effect on arthritis in rats.
Scientific reports. 2018;8(1):3241.
43. Elsherif Y, Alexakis C, Mendall M.
Determinants of weight loss prior
to diagnosis in inflammatory bowel
disease: a retrospective observational  study. Gastroenterology research and
practice. 2014;2014.
44. Videla S, Vilaseca J, Antolín M,
García-Lafuente A, Guarner F,
Crespo E, et al. Dietary inulin
improves distal colitis induced by
dextran sodium sulfate in the rat. The
American journal of gastroenterology.
2001;96(5):1486.
45. Malago JJ, Sangu CL. Intraperitoneal
administration of butyrate prevents
the severity of acetic acid colitis in
rats. Journal of Zhejiang UniversitySCIENCE B. 2015;16(3):224-34.
46. Sun J, Zhang H, Guan L, Zhou H,
Sun M. Alpha-lipoic acid attenuates
trinitrobenzene sulfonic acid-induced
ulcerative colitis in mice. International
journal of clinical and experimental
medicine. 2015;8(1):358.
47. Kuethe F, Figulla HR, Herzau M, Voth
M, Fritzenwanger M, Opfermann T,
et al. Treatment with granulocyte
colony–stimulating factor for
mobilization of bone marrow cells
in patients with acute myocardial
infarction. American heart journal.
2005;150(1):115.
48. Takač B, Mihaljević S, Štefanić
M, Glavaš-Obrovac L, Kibel
A, Samardžija M. Importance
of interleukin 6 in pathogenesis
of inflammatory bowel disease.
Collegium antropologicum.
2014;38(2):659-64.
49. Manna SK, Mukhopadhyay A,
Van NT, Aggarwal BB. Silymarin
suppresses TNF-induced activation
of NF-κB, c-Jun N-terminal kinase,
and apoptosis. The Journal of
Immunology. 1999;163(12):6800-9.
50. Zhao J, Sharma Y, Agarwal R.
Significant inhibition by the
flavonoid antioxidant silymarin
against 12‐O‐tetradecanoylphorbol
13‐acetate–caused modulation
of antioxidant and inflammatory
enzymes, and cyclooxygenase 2 and
interleukin‐1α expression in SENCAR
mouse epidermis: Implications
in the prevention of stage I tumor
promotion. Molecular carcinogenesis.
1999;26(4):321-33.
51. Osuchowski M, Johnson V, He Q,
Sharma R. Alterations in regional
brain neurotransmitters by silymarin, a
natural antioxidant flavonoid mixture,
in BALB/c mice. Pharmaceutical
biology. 2004;42(4-5):384-9.
52. Esmaily H, Hosseini-Tabatabaei A,
Rahimian R, Khorasani R, Baeeri M,
Barazesh-Morgani A, et al. On the
benefits of silymarin in murine colitis
by improving balance of destructive
cytokines and reduction of toxic stress
in the bowel cells. Central European
Journal of Biology. 2009;4(2):204.
53. Onken JE, Greer PK, Calingaert
B, Hale LP. Bromelain treatment
decreases secretion of proinf lammatory cytokines and
chemokines by colon biopsies
in vitro. Clinical Immunology.
2008;126(3):345-52.
54. Zhou Z, Wang L, Feng P, Yin L,
Wang C, Zhi S, et al. Inhibition of
epithelial TNF-α receptors by purified
fruit bromelain ameliorates intestinal
inflammation and barrier dysfunction
in colitis. Frontiers in immunology.
2017;8:1468.
55. Pool-Zobel BL. Inulin-type fructans
and reduction in colon cancer risk:
review of experimental and human
data. British Journal of Nutrition.
2005;93(S1):S73-S90.
56. Shahzad Z, Rouached H, Rakha A.
Combating mineral malnutrition
through iron and zinc biofortification
of cereals. Comprehensive Reviews
in Food Science and Food Safety.
2014;13(3):329-46.
57. Plöger S, Stumpff F, Penner GB,
Schulzke JD, Gäbel G, Martens
H, et al. Microbial butyrate and
its role for barrier function in the
gastrointestinal tract. Annals of the
New York Academy of Sciences.
2012;1258(1):52-9.
58. Kovarik JJ, Tillinger W, Hofer J,
Hölzl MA, Heinzl H, Saemann MD,
et al. Impaired anti‐inflammatory
efficacy of n‐butyrate in patients with
IBD. European journal of clinical
investigation. 2011;41(3):291-8.
59. Diakos C, Prieschl EE, Säemann MD,
Böhmig GA, Csonga R, Sobanov Y,
et al. n-Butyrate inhibits Jun NH
(2)-terminal kinase activation and
cytokine transcription in mast cells.
Biochemical and biophysical research
communications. 2006;349(2):863-8.
60. Assisi R. Combined butyric acid/
mesalazine treatment in ulcerative
colitis with mild-moderate activity.
Results of a multicentre pilot study.
Minerva gastroenterologica e
dietologica. 2008;54(3):231-8.
61. Chen G, Ran X, Li B, Li Y, He D,
Huang B, et al. Sodium Butyrate
Inhibits Inflammation and Maintains
Epithelium Barrier Integrity in a
TNBS-induced Inflammatory Bowel
Disease Mice Model. EBioMedicine.
2018;30:317-25.
62. Hamer HM, Jonkers D, Venema K,
Vanhoutvin S, Troost F, Brummer
RJ. The role of butyrate on colonic
function. Alimentary pharmacology
& therapeutics. 2008;27(2):104-19.
63. Pravda J. Radical induction
theory of ulcerative colitis. World
journal of gastroenterology: WJG.
2005;11(16):2371.
64. Karp SM, Koch TR. Oxidative stress
and antioxidants in inflammatory
bowel disease. Disease-a-Month.
2006;5(52):199-207.
65. McLennan SV, Heffernan S, Wright
L, Rae C, Fisher E, Yue DK, et al.
Changes in hepatic glutathione
metabolism in diabetes. Diabetes.
1991;40(3):344-8.
66. Rezaei N, Eftekhari MH, Tanideh N,
Mokhtari M, Bagheri Z. Protective
Effects of Honey and Spirulina
Platensis on Acetic Acid-Induced
Ulcerative Colitis in Rats. Iranian Red
Crescent Medical Journal. 2018(In
Press).
67. Nieto N, Torres M, Fernandez M,
Giron M, Rios A, Suarez M, et al.
Experimental ulcerative colitis
impairs antioxidant defense system
in rat intestine. Digestive diseases and
sciences. 2000;45(9):1820-7. 

آمار
تعداد مشاهده مقاله: 55
تعداد دریافت فایل اصل مقاله: 83


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب